Comparative Pharmacology
Head-to-head clinical analysis: BRONKAID MIST versus THEOCLEAR L A 130.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKAID MIST versus THEOCLEAR L A 130.
BRONKAID MIST vs THEOCLEAR L.A.-130
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine, the active ingredient, is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Beta-2 receptor activation in bronchial smooth muscle causes bronchodilation. Alpha receptor activation causes vasoconstriction, reducing mucosal edema.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
2 inhalations (200 mcg per inhalation) every 4 hours as needed for bronchospasm. Maximum 12 inhalations in 24 hours.
130 mg orally every 12 hours; extended-release tablet.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours; clinical context: shorter half-life in children, prolonged in hepatic impairment; requires frequent dosing
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Renal: 40-70% unchanged; fecal: minor (biliary) <5%
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Category C
Category C
Bronchodilator
Bronchodilator